[go: up one dir, main page]

BRPI0510817A - protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença - Google Patents

protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença

Info

Publication number
BRPI0510817A
BRPI0510817A BRPI0510817-9A BRPI0510817A BRPI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A BR PI0510817 A BRPI0510817 A BR PI0510817A
Authority
BR
Brazil
Prior art keywords
protease
disease
treating
pharmaceutical composition
diabetes type
Prior art date
Application number
BRPI0510817-9A
Other languages
English (en)
Inventor
Allan Svendsen
Svend Kaasgaard
Kim Borch
Morten Fischer
Dan Pettersson
Peter Colin Gregory
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of BRPI0510817A publication Critical patent/BRPI0510817A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROTEASE, USO DE UMA PROTEASE, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA O TRATAMENTO DE UMA DOENçA O uso farmacêutico de proteases relacionadas a uma protease derivada da Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), opcionalmente em combinação com uma lipase e/ou uma amilase. Os exemplos de indicações médicas são: Tratamento de distúrbios digestivos, insuficiência exócrina pancreática (PEI), pancreatite, fibrose cística, diabete tipo I, e/ou diabete tipo II.
BRPI0510817-9A 2004-05-24 2005-05-24 protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença BRPI0510817A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400810 2004-05-24
DKPA200500101 2005-01-20
PCT/DK2005/000342 WO2005115445A1 (en) 2004-05-24 2005-05-24 Enzymes for pharmaceutical use

Publications (1)

Publication Number Publication Date
BRPI0510817A true BRPI0510817A (pt) 2007-11-20

Family

ID=34968404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510817-9A BRPI0510817A (pt) 2004-05-24 2005-05-24 protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença

Country Status (12)

Country Link
US (2) US20110158976A1 (pt)
EP (1) EP1755656B1 (pt)
JP (1) JP2008500055A (pt)
AT (1) ATE473010T1 (pt)
AU (1) AU2005247061A1 (pt)
BR (1) BRPI0510817A (pt)
CA (1) CA2586222A1 (pt)
DE (1) DE602005022187D1 (pt)
DK (1) DK1755656T3 (pt)
MX (1) MXPA06013239A (pt)
RU (1) RU2389504C2 (pt)
WO (1) WO2005115445A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2539693A1 (en) 2003-10-10 2005-04-21 Novozymes A/S Protease variants
EP2258838A1 (en) 2004-06-21 2010-12-08 Novozymes A/S Nocardiopsis proteases
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
CN101889084A (zh) * 2007-12-04 2010-11-17 诺维信公司 供药学应用的蛋白酶变体
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8153396B2 (en) * 2008-06-03 2012-04-10 Novozymes A/S Method for producing a casein hydrolysate
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105664144B (zh) 2009-01-06 2020-08-11 加尔纳根有限责任公司 治疗或预防金黄色葡萄球菌感染以及根除或减少表面上金黄色葡萄球菌的组合物和方法
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
EP2734633B1 (en) 2011-07-22 2019-05-01 Novozymes North America, Inc. Processes for pretreating cellulosic material and improving hydrolysis thereof
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US20150291656A1 (en) 2012-11-01 2015-10-15 Novozymes A/S Method for removal of dna
EP2910129A1 (de) * 2014-02-21 2015-08-26 Clariant Produkte (Deutschland) GmbH Zusammensetzung für die enzymatische Ölentschleimung
JP6607409B2 (ja) * 2017-03-31 2019-11-20 株式会社東洋新薬 経口用組成物
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK564086A (da) 1986-11-25 1988-06-17 Novo Industri As Enzymatisk detergent-additiv
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
WO1996038170A1 (en) * 1995-05-31 1996-12-05 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
FR2747045B1 (fr) * 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
TR200102784T2 (tr) * 1999-03-17 2002-04-22 Solvay Pharmaceuticals Gmbh Diyabet tedavisi için ilaç
PL203212B1 (pl) * 2000-02-08 2009-09-30 Dsm Ip Assets Bv Zastosowanie trwałej w kwasie proteazy w karmie zwierzęcej oraz w wytwarzaniu kompozycji do stosowania w karmie zwierzęcej, dodatek do karmy zwierzęcej, kompozycja karmy zwierzęcej i sposób obróbki białek roślinnych
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
WO2003106667A2 (en) * 2002-06-12 2003-12-24 Bayer Healthcare Ag Regulation of human subtilase-like serine protease
ATE463563T1 (de) 2003-06-19 2010-04-15 Novozymes As Verbesserte proteasen und verfahren zu ihrer herstellung
WO2004111222A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
PL1639105T5 (pl) 2003-06-19 2013-01-31 Novozymes As Proteazy
CA2539693A1 (en) 2003-10-10 2005-04-21 Novozymes A/S Protease variants

Also Published As

Publication number Publication date
MXPA06013239A (es) 2007-02-28
CA2586222A1 (en) 2005-12-08
DK1755656T3 (da) 2010-10-04
RU2389504C2 (ru) 2010-05-20
JP2008500055A (ja) 2008-01-10
ATE473010T1 (de) 2010-07-15
RU2006145899A (ru) 2008-06-27
AU2005247061A1 (en) 2005-12-08
US20110158976A1 (en) 2011-06-30
EP1755656A1 (en) 2007-02-28
EP1755656B1 (en) 2010-07-07
DE602005022187D1 (de) 2010-08-19
WO2005115445A1 (en) 2005-12-08
US20120207741A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
MX2007015471A (es) Amilasas para uso farmaceutico.
NO20080438L (no) Proteaser til farmasoytisk anvendelse
TW200738256A (en) Lipases for pharmaceutical use
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
NO20065195L (no) Terapeutiske enzymformuleringer og anvendelser derav
EP2175834B8 (en) Glp-1-fc fusion protein formulation
TW200504078A (en) Therapeutically active compounds and their use
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
WO2005111203A3 (en) MUTANT α ΑMYLASES
NZ623123A (en) A process for concentration of a polypeptide
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
HK1053577A2 (en) Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
MXPA06014462A (es) Composiciones y metodos para tratamiento de enfermedades cardiovasculares.
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.